Research programme: cancer therapeutics - LIDDS/Belina Pharma

Drug Profile

Research programme: cancer therapeutics - LIDDS/Belina Pharma

Alternative Names: NZ BELINA

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Belina Pharma; LIDDS
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 30 Jun 2017 LIDDS has patent protection for its NanoZolid® technology
  • 11 Apr 2017 LIDDS and Belina Pharma agree to co-develop cancer therapeutic
  • 11 Apr 2017 Early research in Breast cancer in Sweden (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top